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State of HIV MTCT Prevention
With the dramatic progress in effective
interventions to prevent mother-to-child
HIV transmission (PMTCT), new pediat-
ric HIV infections have become rare in
high-income settings. In the last five years,
PMTCT interventions have been imple-
mented and have undergone rapid scale-
up in low-resource settings, leading
UNAIDS to set a new goal to virtually
eliminate new pediatric HIV infections by
2015 [1]. Virtual elimination has been
defined as a 90% reduction in mother-to-
child transmission (MTCT) from 2009
levels, to ,40,000 new infections annually
and an overall transmission rate of ,5%
in breastfeeding populations. However,
significant implementation challenges re-
main in the 21 priority countries, making
it unlikely that the goal will be met with
the existing interventions alone [2].
The transplacental transfer of maternal
antibodies to infants protects children
from infectious pathogens until immuno-
logical maturity is sufficient to produce
and regulate effective immune responses.
Immunoglobulin transfer continues after
birth through breastfeeding, which also
provides essential nutrients that are not
otherwise available. Unfortunately, during
chronic HIV infection the antibodies
present in the infected host can generally
neutralize virus from three to six months
earlier [3], but are not able to neutralize
contemporaneous circulating strains.
Thus, the antibodies present in the serum
of HIV-infected mothers are not sufficient
to prevent infection from viruses to
which infants are exposed during the
intrapartum period and through breast
milk. In breastfeeding infants born to
HIV-1-infected mothers, overall MTCT
can be as high as 40% with prolonged
breastfeeding in the absence of antiretro-
viral (ARV) prophylaxis [4].
Optimal prevention requires identifica-
tion of maternal HIV infection early in
pregnancy with prompt initiation of ARV
therapy. Studies have demonstrated that
initiation of therapy later than 13 weeks
before delivery is associated with increased
risk of MTCT [5]. However, women in
low-resource countries may miss opportu-
nities to reduce transmission due to missed
HIV screening in antenatal settings, deliv-
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Summary Points
N In 2012, there were 260,000 new pediatric HIV infections worldwide, and it is
unlikely that the goal of global elimination set by UNAIDS for 2015 will be met
with current antiretroviral interventions alone.
N Researchers have recently isolated and characterized broadly neutralizing
antibodies against HIV-1, opening the potential avenue for passive immuniza-
tion as a complement to standard therapy.
N Populations at the highest risk for MTCT, and, therefore more likely to benefit
from new interventions, include women presenting late in pregnancy and/or
lacking antenatal care but it is difficult to enroll and retain such women in trials.
N The target product profile of new interventions should consider issues of
implementation feasibility and access in the context of local health systems,
many of which are resource-constrained.
N A proposed passive immunization trial with the monoclonal antibody VRC01
serves as a useful case study to explore the conduct of trials in infants exposed
to HIV-1 via breastfeeding.
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ery outside of formal medical settings,
HIV infection during pregnancy and
breastfeeding, and the need to extend
breastfeeding to provide the infant with
the best overall chance of survival
(Figure 1).
While formula feeding is recommended
for HIV-infected mothers in industrialized
countries, breastfeeding is the cornerstone
of infant survival in many low-resource
countries. In such settings, the World
Health Organization (WHO) recommends
that HIV-infected mothers should breast-
feed for 12 months with concurrent infant
or maternal ARV prophylaxis to reduce
transmission risk [2]. However, new re-
ports suggest that weaning prior to age 18
months is associated with elevated mor-
bidity and mortality among HIV-exposed,
uninfected children even in clinical trial
settings [4]. Additionally, the use of ARV
prophylaxis by mother or infant during
breastfeeding can reduce but does not
eliminate transmission risk and relies on
strict adherence to daily drug administra-
tion. Breakthrough infections at rates as
high as 2–5% by age six months and 6%
by age 12 months have been observed in
breastfeeding infants of HIV-infected
mothers who have been provided with
triple ARV drug therapy during pregnan-
cy and breastfeeding [4,6].
Although ARV prophylaxis significantly
reduces MTCT, effective implementation
is complicated by the need for prolonged
drug administration and adherence, po-
tential toxicities leading to continued
monitoring requirements, potential for
drug resistance, and inadequate health
care infrastructure. Adherence to therapy
during the postpartum period has been
particularly problematic for women [7,8].
Since 2009, there has been a 38%
decrease in new pediatric HIV-1 infections
across the 21 countries in sub-Saharan
Africa that account for 90% of all new
pediatric infections. However, there were
still 210,000 new pediatric infections in
these countries in 2012, with an estimated
overall transmission rate of 17% (15–
20%). Approximately 40–50% of these
infections were acquired through breast-
feeding [2].
Thus, it appears unlikely that the goal of
global elimination will be met with current
ARV interventions alone, and continued
investigation of preventive interventions to
reduce MTCT, including maternal and/
or infant passive/active immunization,
remains important.
Monoclonal Antibodies Present
New Opportunities
Starting in 2008, a technological revo-
lution has taken place in HIV antibody
research. Development of next-generation
sequencing, advances in in vitro B cell
clonal amplification, and high-throughput
neutralization assays allow investigators to
study the diversity of antibody responses in
HIV-infected subjects and to identify
antibodies with long-sought properties.
Using RT-PCR, both the heavy and light
chain immunoglobulin (Ig) genes can be
amplified from single B cells and cloned
into expression vectors [9]. These tech-
niques allow large-scale isolation and
synthetic production of human monoclo-
nal antibodies (mAb) by transfection of
producer cells in vitro. As a result, the field
that had identified only four broadly
neutralizing antibodies (bNAbs) in the past
25 years has suddenly found dozens of new
bNAbs, some of which were two orders of
magnitude more potent, with much great-
er breadth than their predecessors [10–
13]. Most of the HIV-1-specific bNAbs
found to date have unusual properties
including long heavy chain CDR3 loops,
extensive somatic hypermutation, and
glycan dependence, which may explain
why it has been hard to induce bNAbs by
vaccination and why the neutralizing
antibody response to natural infection lags
behind the evolution of neutralization-
resistant genetic variants [14].
Whether the newly discovered antibod-
ies could be used to treat or prevent HIV-
1 infection is a question that is being
actively explored (Box 1) [15]. Historically,
passively administered antibodies have
been shown to have an excellent safety
profile and to protect against multiple
viruses, including cytomegalovirus, vari-
cella zoster virus, poliovirus, hepatitis A
and B viruses, measles virus, Junin virus,
rabies virus, and respiratory syncytial virus
(RSV). Polyclonal immunoglobulins have
also been shown to be effective in
preventing perinatal transmission of sev-
eral viruses. For example, cytomegalovirus
hyperimmune globulin administered to
pregnant mothers infected with cytomeg-
alovirus during pregnancy was shown to
reduce perinatal transmission by 50%
[16]. Before the vaccine for hepatitis B
was available, the recommended interven-
tion to prevent perinatal hepatitis B
transmission was to administer hepatitis
B immunoglobulin to all infants born to
hepatitis B surface antigen positive moth-
ers at zero, three, and six months after
birth [17]; even with active hepatitis B
vaccination, a single dose of hepatitis B
immunoglobulin continues to be recom-
mended. Administration of varicella zoster
hyperimmune globulin to infants born to
mothers with varicella around the time of
delivery was also shown to reduce the
chances of perinatal transmission of vari-
cella zoster virus [18]. Compared to
polyclonal immunoglobulin preparations,
mAbs are considered to be safer because
they are not derived from blood products.
Several mAbs are now in clinical develop-
ment, and two mAbs are currently
licensed for use against the microbial
pathogens RSV and anthrax [19,20].
Figure 1. While 77% of women in sub-Saharan Africa have at least one antenatal care
(ANC) visit, most are not seen until the second or third trimester [34]. In contrast, the
majority of women in the United States access antenatal care during the first trimester [35].
doi:10.1371/journal.pmed.1001616.g001
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Studies of polyclonal HIV-1 immuno-
globulin for PMTCT have not demon-
strated efficacy [21,22]. However, only a
small fraction of total IgG in these
preparations was HIV-1-specific, and sera
were selected based on the presence of
antibodies to p24, an internal protein that
is not a target for neutralizing antibodies.
The bNAbs that are proposed for use in
the new studies are known to be effective
in vitro at concentrations that can be
reached in blood after a single injection.
They neutralize a diversity of HIV strains,
including ‘‘transmitter founder’’ viruses—
clones reconstructed from phylogenetic
data and representing the individual
virions that established infections in the
studied individuals. Moreover, recent ex-
periments in macaques have shown that
bNAbs can protect against mucosal viral
challenge in rhesus macaques [23]. Thus,
the new approaches that are based on
monoclonals may be expected to be more
effective than past attempts with polyclon-
al sera.
Although ARV prophylaxis is the
foundation for PMTCT, active or passive
immunization could provide a safe and
durable adjunctive intervention to further
reduce transmission, particularly during
breastfeeding. If efficacious, these ap-
proaches have the advantage of being
less reliant on patient adherence than
interventions requiring daily administra-
tion. Adding passive administration of
bNAbs to ARV treatment in PMTCT is
attractive because of the safety track
record for immunoglobulin prophylaxis
in general, the long half-life that may
cover gaps in ARV adherence, product
stability, and the familiarity of practition-
ers and patients with immunoglobulin
treatment to prevent viral diseases. In-
fants exposed to HIV via their mothers
represent a population that may be
particularly suited to benefit from passive
immunizations because the fact of expo-
sure and duration of exposure can be
clearly identified and because the re-
quired dose for an infant is smaller than
for an adult.
Bridging Scientific Plausibility
and Clinical Practice
The jump from the scientific plausibility
of a biomedical intervention to feasible
clinical practice is often complex. A
January 2013 meeting in Entebbe,
Uganda organized by the Global HIV
Vaccine Enterprise and others engaged
stakeholders around potential challenges
in studying and implementing active and/
or passive immunization to further reduce
MTCT in low-resource settings [24]. A
number of key considerations were raised,
which are applicable to all efforts to
develop additional prevention modalities,
either by active or passive immunization.
The Choice of the Product
The new technologies that bolstered
rapid progress in discoveries of human
antibodies against HIV-1 are being im-
proved, and new mAbs are being identi-
fied. Combinations of antibodies can be
used to improve the potency and expand
the breadth of viral coverage even further.
The choice to develop a particular anti-
body or a combination of antibodies for
clinical research has to take multiple
factors into account. Among these are
the activity of the product against viruses
in the target population, auto-reactivity,
administration route, half-life, the ability
to manufacture the product in sufficient
amounts, and the current stage of product
development. Right now, one monoclonal
antibody with broad neutralizing activity,
VRC01, is slightly more advanced in the
development process than other products,
and phase I clinical evaluation in adults
has begun (see Box 1). However, in the
future, the number of potential options
will undoubtedly increase and make
choices more difficult, requiring consider-
ation of cost:benefit, risk:benefit, and
timing.
Clinical Path to Testing Efficacy in
Infants
The primary objective for passive ad-
ministration of a monoclonal bNAb to
infants would be to prevent infection. The
mAb would therefore be given to the
infant immediately after delivery with the
hope of preventing some intrapartum
transmission events and to establish ade-
quate levels of neutralizing activity in the
infant’s serum to prevent breast milk
transmission. The mAb would specifically
not be administered to mothers to avoid
the possibility of producing neutralization-
resistant variants. Before performing these
studies in high-risk infants, a series of
safety and pharmacokinetic studies will
need to be done in adults. Figure 2
outlines one potential sequence of trials
that would provide the safety and phar-
macokinetic data needed to support a
phase IIb efficacy trial, and would also
provide logistical data to inform the
feasibility analysis being done in parallel
as outlined below. Evaluation in HIV-
uninfected adults could proceed to testing
a small cohort of HIV-exposed infants
before determining the dose and schedule
for a phase IIb test-of-concept efficacy trial
in high-risk infants. Studying the mAb in
HIV-infected adults would be informative
for two major reasons. First, because some
infants may be unknowingly infected at
birth, safety data for mAbs in the presence
of HIV infection will be needed. Second,
the impact on viral replication and
pathogenesis could be assessed to indirect-
ly support the primary objective of the
prevention trial. Because the typical half-
Box 1. Development of VRC01 mAb for HIV-1 PMTCT
VRC01 is a human mAb directed to the CD4 binding site of HIV-1 gp120 [13,30–
33]. It has broad neutralizing capacity with over 90% of strains from a 200 virus
panel neutralized at 50 mg/ml and excellent potency with over 70% of strains
neutralized at ,1 mg/ml [13]. It appears to effectively neutralize transmitted
strains of HIV-1. In Zambian mother-infant pairs in which HIV-1 transmission
occurred, VRC01 neutralized 18/23 (78%) isolates from infants, even though only
12/23 (52%) maternal isolates were neutralized [36]. Unlike some other bNAbs,
VRC01 has been shown to have no auto-reactivity or tissue cross-reactivity in vitro.
In animal model studies, VRC01 has been evaluated in adult and infant macaques.
Adults treated with 20 mg/kg of the antibody were consistently protected from
all rectal and vaginal challenges with SHIVSF162(P3) (a virus relatively difficult to
neutralize) when serum levels were above 40 mg/ml and were partially protected
at doses of 5 mg/kg. Protection from SHIVBAL (a relatively easy to neutralize
virus) occurred with doses of less than 1 mg/kg and VRC01 mAb serum levels
above 1 mg/ml (personal communication, B. Graham to authors). A small study in
seven infant macaques (one-month-old) showed that six animals receiving VRC01
were protected from oral SHIVSF162(P3) challenge (personal communication, N.
Haigwood to authors). These doses and the range of mAb levels in serum have
been achievable in humans treated with other mAbs.
For these reasons, VRC01 is being considered for evaluation as an adjunct to ARVs
in mother-infant pairs with high risk of transmission. Currently, VRC01 has been
manufactured at a concentration of 100 mg/ml and phase I pharmacokinetic
evaluation in HIV-infected and uninfected adults has begun.
Antibodies to Reduce Mother-to-Child HIV Transmission
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life of a mAb in vivo is 21–24 days, the
dosing would be monthly and continue
until the completion of breastfeeding.
Therefore, multi-dose safety data from
early phase trials will be needed. These
studies would take up to 18 months and
require careful planning and coordination
with clinical investigators and stakeholders
at trial sites, in addition to ongoing
communication with and guidance from
regulatory agencies.
Challenges for Conducting Efficacy
Trials
Passive immunization is proposed to
complement and improve upon the exist-
ing PMTCT interventions. Therefore, in
clinical trials the mAbs must be tested in
combination with local standard of care
for HIV prevention. Our estimates show
that, with currently observed rates of
pediatric HIV-1 infections in infants born
to HIV-infected mothers who receive
antiretroviral therapy starting either late
in pregnancy or postpartum (estimated to
be 3–5% based on several clinical trials
[25–27]), a study would need to enroll
1,000–3,000 mother-infant pairs to be able
to detect efficacy of 60% or more for the
adjunct intervention. The variability in the
required sample size depends on the
expected transmission rate, which will be
dependent on inclusion criteria that deter-
mine the level of transmission risk, and on
estimated attrition rate. One of the key
populations that would need to be enrolled
in the study is women presenting late to
antenatal clinics: that is, women with a
high risk of transmission even with optimal
ARV intervention. Recruitment into the
trial will have to be done during the short
time between their arrival and delivery, a
time when they are particularly vulnerable
and may be dealing with the HIV
diagnosis. Retaining these women in a
trial that requires multiple, regular visits
will also be challenging because late
presentation is usually caused by socioeco-
nomic disenfranchisement and difficulty
accessing medical care.
Cost Considerations
mAbs are expensive to produce, and it
has been argued that the product would not
be affordable in resource-limited settings for
the population that will need it most [28].
However, any cost-benefit analysis should
compare the short-term costs of delivering
the prophylaxis with the costs of lifelong
treatment and care for an HIV-infected
infant. These costs vary widely from one
setting to another and will continue to
decrease in the future, as both the costs for
treatment and for bulk production of
antibodies are rapidly improving.
Feasibility for Integration with
Current Standard of Care
The goal of product development
should be to seek a target profile that will
be feasible with minor changes in the
countries’ health care infrastructure. Pas-
sive immunization would provide protec-
tion that that does not depend on strict
daily adherence to ARV drugs; thus,
passive immunization would be an impor-
tant adjunct to increase efficacy of current
ARV regimens. However, it requires the
product to be regularly administered
parenterally by qualified medical person-
nel and, therefore, attention would need to
be paid to injection safety, a reliable
supply chain, and a plan for medical
waste. Required frequency of administra-
tion will be a critical factor in product
development. Pharmacodynamic proper-
ties of VRC01 suggest that administration
will be needed every four weeks to
maintain the concentration that is expect-
ed to be protective. Even if these admin-
istrations are timed to coincide with
routine infant immunization schedules as
much as possible, additional medical visits
would be required, putting additional
burden on families and health care
systems. The situation is further compli-
cated by the fact that many of the infants
who would benefit most from this inter-
vention live in communities with limited
access to routine health care. The first
translation efforts are focusing on proof-of-
concept studies, but for optimal imple-
mentation, final products should be
effective with less frequent administration.
Fortunately, new approaches are being
developed to extend the half-lives of
monoclonal antibodies in vivo [29].
Future Goals and Directions
Eliminating pediatric HIV infections
worldwide is an achievable goal that
needs to be approached from multiple
Figure 2. One possible clinical pathway for testing monoclonal antibodies in infants. Safety, pharmacokinetics (PK), and biological effect
on virus populations are initially assessed in HIV-positive adults. Dosing is further refined in studies in HIV-negative adults and infants. This
information is used to design an efficacy study in HIV-exposed infants as an adjunct to standard ARV treatment and prophylaxis.
doi:10.1371/journal.pmed.1001616.g002
Five Key Papers in the Field
2013 UNAIDS progress report [2]. The report shows current progress in reducing
MTCT in 21 priority countries.
Kesho Bora Study Group, de Vincenzi I (2011) [26]. The study showed excellent
efficacy of triple-drug therapy for PMTCT, but at the same time showed that, even
with this intervention, there is still a 5–6% transmission rate in the breastfeeding
population.
Walker et al. (2009) [11]. The paper was the first in a series of papers from multiple
laboratories describing isolation of the next generation of broad and potent
neutralizing antibodies against HIV-1.
Wu et al. (2010) [13]. The authors used a specially designed envelope protein to
isolate multiple broadly neutralizing antibodies, including VRC01.
Klein et al. (2013) [15]. The review discusses the potential applications of
monoclonal antibodies in HIV treatment and prevention.
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directions. Improving delivery of proven
interventions is critical and provides
immediate return on investment. At the
same time, the public health community
should not become complacent in think-
ing that ARV drugs will provide adequate
protection in all scenarios. Researchers
need to actively explore new approaches
that will complement and improve those
that already exist. The discovery and
isolation of extremely potent bNAbs
present an opportunity that should be
explored. Clinical trials are currently
being planned that will provide valuable
information about both the scientific and
the logistical feasibility of bringing these
discoveries into clinical use.
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